Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling

Elizabeth J. Culp, Nicholas Waglechner, Wenliang Wang, Aline A. Fiebig-Comyn, Yen-Pang Hsu, Kalinka Koteva, David Sychantha, Brian K. Coombes, Michael S. Nieuwenhze, Yves V. Brun and Gerard D. Wright ()
Additional contact information
Elizabeth J. Culp: McMaster University
Nicholas Waglechner: McMaster University
Wenliang Wang: McMaster University
Aline A. Fiebig-Comyn: McMaster University
Yen-Pang Hsu: Indiana University
Kalinka Koteva: McMaster University
David Sychantha: McMaster University
Brian K. Coombes: McMaster University
Michael S. Nieuwenhze: Indiana University
Yves V. Brun: Indiana University
Gerard D. Wright: McMaster University

Nature, 2020, vol. 578, issue 7796, 582-587

Abstract: Abstract Addressing the ongoing antibiotic crisis requires the discovery of compounds with novel mechanisms of action that are capable of treating drug-resistant infections1. Many antibiotics are sourced from specialized metabolites produced by bacteria, particularly those of the Actinomycetes family2. Although actinomycete extracts have traditionally been screened using activity-based platforms, this approach has become unfavourable owing to the frequent rediscovery of known compounds. Genome sequencing of actinomycetes reveals an untapped reservoir of biosynthetic gene clusters, but prioritization is required to predict which gene clusters may yield promising new chemical matter2. Here we make use of the phylogeny of biosynthetic genes along with the lack of known resistance determinants to predict divergent members of the glycopeptide family of antibiotics that are likely to possess new biological activities. Using these predictions, we uncovered two members of a new functional class of glycopeptide antibiotics—the known glycopeptide antibiotic complestatin and a newly discovered compound we call corbomycin—that have a novel mode of action. We show that by binding to peptidoglycan, complestatin and corbomycin block the action of autolysins—essential peptidoglycan hydrolases that are required for remodelling of the cell wall during growth. Corbomycin and complestatin have low levels of resistance development and are effective in reducing bacterial burden in a mouse model of skin MRSA infection.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
https://www.nature.com/articles/s41586-020-1990-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:578:y:2020:i:7796:d:10.1038_s41586-020-1990-9

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-020-1990-9

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().